<code id='A09C40868A'></code><style id='A09C40868A'></style>
    • <acronym id='A09C40868A'></acronym>
      <center id='A09C40868A'><center id='A09C40868A'><tfoot id='A09C40868A'></tfoot></center><abbr id='A09C40868A'><dir id='A09C40868A'><tfoot id='A09C40868A'></tfoot><noframes id='A09C40868A'>

    • <optgroup id='A09C40868A'><strike id='A09C40868A'><sup id='A09C40868A'></sup></strike><code id='A09C40868A'></code></optgroup>
        1. <b id='A09C40868A'><label id='A09C40868A'><select id='A09C40868A'><dt id='A09C40868A'><span id='A09C40868A'></span></dt></select></label></b><u id='A09C40868A'></u>
          <i id='A09C40868A'><strike id='A09C40868A'><tt id='A09C40868A'><pre id='A09C40868A'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:1
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          Readout Newsletter: What happened with Sarepta's Duchenne data
          Readout Newsletter: What happened with Sarepta's Duchenne data

          AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          For BCIs, commercial hurdles may be bigger than scientific ones

          AdevicecomponentfromParadromicsInc.,oneofthemainbrain-computerinterfaceplayersracingtogettomarket.Co